Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue

Area of Science:

• Oncology
• Cancer Biology
• Genomics

Background:

• Non-small cell lung cancer (NSCLC) with EGFR mutations is often treated with tyrosine kinase inhibitors like osimertinib.
• Acquired resistance remains a significant challenge in NSCLC treatment, leading to disease progression.
• Understanding resistance mechanisms is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate the frequency and types of histologic transformations in EGFR-mutant NSCLC patients progressing on first-line osimertinib.
• To emphasize the importance of tissue biopsies in identifying resistance mechanisms.
• To highlight the need for novel therapeutic approaches to overcome or prevent treatment resistance.

Main Methods:

• Analysis of matched pre- and posttreatment tissue biopsies from NSCLC patients.
• Histopathologic examination to identify histologic transformations.
• Correlation of transformations with clinical outcomes on osimertinib therapy.

Main Results:

• Histologic transformations, including small-cell carcinoma and squamous transformation, were unexpectedly common in patients progressing on first-line osimertinib.
• Tissue testing revealed these transformations as a key mechanism of resistance.
• The findings underscore the limitations of current therapies in preventing resistance.

Conclusions:

• Histologic transformation is a frequent event in EGFR-mutant NSCLC treated with osimertinib.
• Relying solely on targeted therapy without addressing resistance mechanisms can lead to treatment failure.
• Future research should focus on strategies to prevent resistance and improve long-term patient outcomes.